These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 6818930)

  • 21. Assessment of the effectiveness of antipseudomonas biological management in the control of infection in burn patients.
    Gonzáles Ayala SE; Daroda M; Villa J; Cecchini E; Vich J
    Panminerva Med; 1983; 25(3):203-8. PubMed ID: 6422426
    [No Abstract]   [Full Text] [Related]  

  • 22. [Vaccine therapy against Pseudomonas aeruginosa].
    Kurashige T; Tomoda T
    Nihon Rinsho; 1991 Oct; 49(10):2421-4. PubMed ID: 1749099
    [No Abstract]   [Full Text] [Related]  

  • 23. Clinical use of monovalent vaccines in the treatment of Pseudomonas aeruginosa infection.
    De Fajardo CL; Delfino AH; Laborde HF
    Prog Immunobiol Stand; 1971; 5():425-7. PubMed ID: 4633970
    [No Abstract]   [Full Text] [Related]  

  • 24. Pseudomonas aeruginosa infection: pathogenesis and therapy.
    Pennington JE
    Compr Ther; 1979 May; 5(5):14-22. PubMed ID: 110508
    [No Abstract]   [Full Text] [Related]  

  • 25. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy.
    Wright A; Hawkins CH; Anggård EE; Harper DR
    Clin Otolaryngol; 2009 Aug; 34(4):349-57. PubMed ID: 19673983
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Use of hyperimmune anti-Pseudomonas plasma in the treatment of infectious complications].
    Grishina IA; Terekhova RP; Marchuk AI; Elagina LV; Ostrovskaia EV; Nezhlukto AIa
    Khirurgiia (Mosk); 1990 Nov; (11):121-3. PubMed ID: 2127294
    [No Abstract]   [Full Text] [Related]  

  • 27. [Characteristics and epidemiological significance of the Pseudomonas aeruginosa strains isolated in Rumania from sporadic cases and nocosomial infections].
    Meitert E; Meitert T
    Arch Roum Pathol Exp Microbiol; 1972 Sep; 31(3):443-8. PubMed ID: 4198514
    [No Abstract]   [Full Text] [Related]  

  • 28. [Therapy against intractable respiratory infections with Pseudomonas aeruginosa].
    Nakata K
    Nihon Kyobu Shikkan Gakkai Zasshi; 1989 Mar; 27(3):293-8. PubMed ID: 2515331
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of carbenicillin, gentamicin and vaccines on rats experimentally burned and infected with Pseudomonas aeruginosa.
    Toama MA; Hamed IM; Ashour SM
    Pharmazie; 1980; 35(4):228-30. PubMed ID: 6773076
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early rise of anti-pseudomonas antibodies and a mucoid phenotype of pseudomonas aeruginosa are risk factors for development of chronic lung infection--a case control study.
    Pressler T; Frederiksen B; Skov M; Garred P; Koch C; Høiby N
    J Cyst Fibros; 2006 Jan; 5(1):9-15. PubMed ID: 16412706
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pseudomonas aeruginosa infection after living-donor liver transplantation in adults.
    Hashimoto M; Sugawara Y; Tamura S; Kaneko J; Matsui Y; Kokudo N; Makuuchi M
    Transpl Infect Dis; 2009 Feb; 11(1):11-9. PubMed ID: 18811632
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Severe lesions of the petrous bone caused by pseudomonas aeruginosa].
    Lamas G; Poignonec S; Bosquet F; Daoui B; Bokowy C; Halimi P
    Ann Otolaryngol Chir Cervicofac; 1990; 107(5):341-4. PubMed ID: 2121085
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Pseudomonas multicomponent vaccine in major burn patients].
    Mizuno H; Ashikawa K
    Nihon Rinsho; 1991 Oct; 49(10):2425-30. PubMed ID: 1749100
    [No Abstract]   [Full Text] [Related]  

  • 34. [Effectiveness of a polyvalent corpuscular Pseudomonas aeruginosa vaccine, antibiotics and their combinations in experimental chronic Pseudomonas aeruginosa infection].
    Vetkova LG; Antsiferova NG; Radkevich SA; Moroz AF
    Zh Mikrobiol Epidemiol Immunobiol; 1985 Mar; (3):51-6. PubMed ID: 3922187
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Immunogenic properties of a polyvalent vaccine against Pseudomonas aeruginosa].
    Serafińska D; Bukowska D; Sokołowska K; Nasiłowski W
    Pol Tyg Lek; 1980 Jul; 35(27):1013-5. PubMed ID: 6775310
    [No Abstract]   [Full Text] [Related]  

  • 36. Experimental chronic Pseudomonas aeruginosa lung infection in rats. Non-specific stimulation with LPS reduces lethality as efficiently as specific immunization.
    Lange KH; Hougen HP; Høiby N; Fomsgaard A; Rygaard J; Johansen HK
    APMIS; 1995 May; 103(5):367-74. PubMed ID: 7654361
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Clinical use of a Soviet polyvalent corpuscular pyocyanic vaccine for the prevention of Pseudomonas aeruginosa infection in thermal burn victims].
    Gerasimova LI; Moroz AF; Radkevich SA; Sveshnikov AI; Mizikin EV
    Khirurgiia (Mosk); 1980 Nov; (11):36-41. PubMed ID: 6777578
    [No Abstract]   [Full Text] [Related]  

  • 38. [Ways of increasing the effectiveness of antibacterial drugs in the treatment of pseudomonas infection in burns].
    Moroz AF; Vinogradova OI; Bekbergenov BM; Brodinova NS; Antsiferova NG
    Khirurgiia (Mosk); 1976 Jun; (6):81-8. PubMed ID: 827653
    [No Abstract]   [Full Text] [Related]  

  • 39. [Pseudomonas aeruginosa ocular infection].
    Oomomo A
    Nihon Rinsho; 1991 Oct; 49(10):2405-9. PubMed ID: 1749097
    [No Abstract]   [Full Text] [Related]  

  • 40. [Chemical components of pathogens and the mechanism of their virulence: Pseudomonas aeruginosa vaccine].
    Homma Y; Tanimoto H
    Nihon Rinsho; 1986 Sep; 44(9):2016-21. PubMed ID: 3099035
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.